ILMN Stock Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
Notes are coming soon
Illumina, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$197.58|
|52 Week High||US$338.40|
|52 Week Low||US$171.20|
|1 Month Change||8.48%|
|3 Month Change||-16.42%|
|1 Year Change||-35.22%|
|3 Year Change||-30.89%|
|5 Year Change||1.32%|
|Change since IPO||26.17%|
Recent News & Updates
|ILMN||AT Life Sciences||AT Market|
Return vs Industry: ILMN underperformed the Austrian Life Sciences industry which returned -18.6% over the past year.
Return vs Market: ILMN underperformed the Austrian Market which returned -10.5% over the past year.
|ILMN Average Weekly Movement||6.2%|
|Life Sciences Industry Average Movement||6.1%|
|Market Average Movement||4.4%|
|10% most volatile stocks in AT Market||8.7%|
|10% least volatile stocks in AT Market||2.5%|
Stable Share Price: ILMN is more volatile than 75% of Austrian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ILMN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.
Illumina, Inc. Fundamentals Summary
|ILMN fundamental statistics|
Is ILMN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ILMN income statement (TTM)|
|Cost of Revenue||US$1.42b|
Last Reported Earnings
Oct 02, 2022
Next Earnings Date
Feb 07, 2023
|Earnings per share (EPS)||-26.40|
|Net Profit Margin||-88.36%|
How did ILMN perform over the long term?See historical performance and comparison